Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout
Executive Summary
Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.
You may also be interested in...
Reading The FTC Tea Leaves: Investors Await Insights For M&A
Pfizer and Amgen both have large M&A deals under regulatory review, and investors will be eager to hear updates on how those transactions are progressing during Q2 reporting.
Biopharma M&A’s Busy Pace Expected To Continue During 2023’s Second Half
Analysts from PwC see multiple factors that should continue to drive bolt-on deals valued at $1bn or more, but heightened FTC scrutiny of large M&A may discourage bigger transactions.
Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”
Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.